Novel Foods Group, based in Abu Dhabi and a leader in the alternative proteins sector, along with global engineering firms, has agreed to begin planning a $500 million biotech production site in the UAE. The agreement, signed during the Healthy Innovation Conference in Dubai, involves Novel Foods, Glatt Group, BioEngineering AG, and CB Consultancy AG.
This new facility will focus on producing brazzein, a natural sweet protein significantly sweeter than traditional sugar. The use of brazzein is growing amid a global increase in demand for alternative sugars, with brazzein offering a genuine sugar taste without sacrificing health.
Traditionally derived from West African berries, the challenges in harvesting are being addressed through precision fermentation. Novel Foods Group aims to provide sweetness without compromising health or taste and is actively engaged in creating brazzein-infused recipes and collecting consumer feedback through partnerships with universities and research institutions. Their R&D center in Dubai supports regional product development and co-creation efforts.
Please find original version of article below:
https://www.tradearabia.com/news/HEAL_419744.html
The information shared by the Islamic Organization for Food Security (“IOFS”) on iofs.org.kz (the “Site”) serves solely for general informational purposes. As a non-profit international organization, IOFS provides this information in good faith, with no intention to commercialize, profit, or exploit any content. Commercial use, including reselling, charging for access, redistribution, or creating derivative works, such as unofficial translations based on these documents, is strictly prohibited. All posts, publications, texts, and any other information on the Site, owned by authors and references, are appropriately linked.
IOFS disclaims any liability for loss or damage of any kind resulting from the use of the Site. Your understanding and compliance with these terms contribute to maintaining the informative and non-commercial nature of our platform.
